Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
01:31pm, Friday, 13'th Oct 2023
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.
11:34am, Friday, 13'th Oct 2023
Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the resu
1 Dividend Legend Potentially Set To Soar And 2 To Ignore
07:25am, Friday, 13'th Oct 2023
1 Dividend Legend Potentially Set To Soar And 2 To Ignore
7 Stocks to Buy With Your 2024 Social Security Increase
06:53pm, Thursday, 12'th Oct 2023
The Social Security cost of living adjustment (COLA), which is tied to the rate of inflation, was a whopping 8.7% this year. It is expected to be around 3.2% for 2024.
Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
04:35pm, Thursday, 12'th Oct 2023
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for pro
Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?
10:31am, Thursday, 12'th Oct 2023
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the
3 Super Safe Dividend Stocks That Have Been Making Payments for Decades
09:15am, Thursday, 12'th Oct 2023
Eli Lilly, Coca-Cola, and Microsoft are solid dividend stocks that have grown their payouts for years. Moreover, these are highly profitable companies whose dividends still have plenty of room to rise
5 Most Overvalued Mega-Caps According To Quant: Buy, Sell, Hold?
08:52am, Thursday, 12'th Oct 2023
Seeking Alpha's quant computer ranking tool identifies Amazon, NVIDIA, Tesla, Eli Lilly, and Visa as the most overvalued mega-cap stocks. Earnings, EBITDA, book value, and dividend yields as value bac
Eli Lilly stock hits new high on positive Crohn's disease study results
08:35am, Thursday, 12'th Oct 2023
Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage study to test it as a treatment for moderately to severely acti
Eli Lilly (LLY) stock price is flying: buy the Nvidia of pharma
08:13am, Thursday, 12'th Oct 2023
Eli Lilly (NYSE: LLY) stock price has quietly become one of the best-performing stocks in the past few years. The shares are trading at their all-time high of $605.28, higher than the 2009 low of $14.
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
08:01am, Thursday, 12'th Oct 2023
But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?
Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
05:33pm, Wednesday, 11'th Oct 2023
Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and has two other medications in phase 3 clinical studies. The GLP-1 therapy market is projected to reach $150 bil
Why Eli Lilly Stock Is Jumping Today
11:45am, Wednesday, 11'th Oct 2023
Novo Nordisk announced it's stopping a kidney outcomes trial for Ozempic earlier than planned. Investors are hoping that Novo Nordisk's positive development will translate to success for Lilly.
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
09:37am, Wednesday, 11'th Oct 2023
Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
Eli Lilly gets $14bn boost from Ozempic data - here's what's happened
08:53am, Wednesday, 11'th Oct 2023
Eli Lilly and Co (NYSE:LLY) shares were trading 2.6% higher pre-market after a positive read-across from a key trial read-out from its main rival in the weight-loss market. Denmark's Novo Nordisk (NYS
